IMM 1.64% 30.0¢ immutep limited

dendreon's provenge results meet target, page-7

  1. 12,893 Posts.
    1st cancer trial involving imunotherapy. They will update their filings with the FDA in the fourth quarter of this year. Patients have advanced prostate cancer; increased survival rates are key here. Very significant results here. Watch Dendreon on the Nasdaq Code:DSDN tonight.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.